ATNAA Label Centers on Rapid IM Treatment for Organophosphorus Nerve Agent Poisoning
ATNAA, the atropine and pralidoxime chloride autoinjector, is positioned as an emergency antidote for adults poisoned by susceptible organophosphorus nerve agents with anticholinesterase activity. The label keeps the clinical purpose narrow and urgent: give treatment as soon as symptoms appear, then move immediately to definitive medical care. In toxicology, delay is the enemy because organophosphorus exposure drives a cholinergic crisis that can rapidly compromise the airway, secretions, neuromuscular function, and cardiovascular stability.
The formulation pairs two pharmacologic responses to the same pathophysiology. Atropine blocks muscarinic receptors and counters the excess parasympathetic tone responsible for bronchorrhea, bradycardia, and other muscarinic manifestations. Pralidoxime chloride acts as a cholinesterase reactivator, restoring enzyme function when the bond between the nerve agent and acetylcholinesterase remains susceptible to reversal. In practical bedside terms, the device is meant to interrupt the toxic cascade fast enough to keep the patient breathing and perfusing while higher-level care is arranged.
Dosing Is Built Around Symptom Severity and Immediate Field Use
The dosing instructions are explicit and reflect the tempo of nerve agent exposure. For mild symptoms, one injection is self-administered intramuscularly into the lateral thigh muscle or buttocks. If severe symptoms develop after that first dose, or if mild symptoms do not resolve, a buddy gives two additional injections in rapid succession. When severe symptoms are present from the outset, three injections are administered immediately in rapid succession into the lateral thigh muscle or buttocks.
This is not a maintenance regimen. It is an initial intervention designed for the first minutes of a poisoning event, when secretions, bronchospasm, muscle weakness, and central nervous system effects can outpace normal emergency response. The label also states that three single-dose autoinjectors should be available for each service member at risk, a reminder that the product is intended for environments where exposure may be sudden, severe, and operationally constrained.
A single delayed dose can change the trajectory of the entire encounter.
Autoinjector Strength Reflects the Combined Antidote Strategy
Each single-dose autoinjector contains atropine 2.1 mg/0.7 mL and pralidoxime chloride 600 mg/2 mL. The combined delivery allows both arms of the antidotal strategy to be deployed without separate preparation under pressure. For frontline use, that matters because nerve agent poisoning often unfolds in settings where time, dexterity, and visibility are limited.
The label lists no contraindications. In a poisoning emergency, the absence of listed contraindications reinforces the expectation that benefit may outweigh risk when exposure is suspected and clinical deterioration is unfolding. Even so, the warnings section makes clear that this is not a benign medication. Its pharmacology is potent enough to produce clinically relevant adverse effects, especially in vulnerable patients.
Cardiovascular, Thermal, Ocular, Urinary, and Pulmonary Risks Require Attention
The most immediate warnings focus on cardiovascular risk. Tachycardia, palpitations, premature ventricular contractions, flutter, and fibrillation can occur, and caution is advised in individuals with known cardiovascular disease or conduction problems. Atropine’s antimuscarinic effect explains this concern: once vagal restraint is removed, heart rate and ectopy may rise, especially in stressed patients already in a hyperadrenergic toxic state.
Heat injury is another concrete hazard. Because atropine may inhibit sweating, hyperthermia can follow, particularly if the patient is physically active or exposed to heat. In operational settings, that warning has immediate relevance. A treated patient who is still in a hot environment can move from cholinergic collapse into thermoregulatory failure if cooling and rest are not addressed.
The label also warns about acute glaucoma, urinary retention in those with bladder outflow obstruction, and potential worsening of pyloric stenosis, which may convert to complete obstruction. In chronic lung disease, atropine may thicken bronchial secretions and form dangerous viscid plugs, so respiratory monitoring is essential. This is an important paradox of antimuscarinic rescue: the same property that dries secretions can also make them harder to clear.
Adverse Reactions Track the Known Pharmacology of Both Components
Common adverse reactions attributed to atropine include dry mouth, blurred vision, dry eyes, photophobia, confusion, headache, and dizziness. Pralidoxime chloride adds its own adverse effect profile, including changes in vision, dizziness, headache, drowsiness, nausea, tachycardia, increased blood pressure, muscular weakness, dry mouth, emesis, rash, dry skin, hyperventilation, decreased renal function, excitement, manic behavior, and transient elevations of liver enzymes and creatine phosphokinase.
The overlap between therapeutic effect and toxicity is clinically recognizable. Dry mouth, tachycardia, and mental status changes can be expected from atropine’s anticholinergic action, while pralidoxime’s neurologic and autonomic effects broaden the monitoring burden. For clinicians, the label makes clear that symptom relief does not eliminate the need for observation; it often creates the need for it.
Inadvertent injection and injection-site reactions are also addressed in the full labeling, another reminder that autoinjector use carries procedural risk even before the toxicologic crisis is fully controlled.
Drug Interactions and Special Populations Add More Caution to Rescue Use
A specific interaction is listed with succinylcholine and mivacurium, where accelerated reversal of neuromuscular blocking effects may occur. That interaction is clinically relevant in perioperative or critical care settings, where paralysis, intubation, or procedural sedation may intersect with toxin management. Monitoring is advised when these agents are used together.
Special population guidance remains limited but clinically useful. Geriatric individuals may be more susceptible to atropine’s effects, which fits the broader understanding of reduced physiologic reserve and greater sensitivity to anticholinergic burden in older adults. Pregnancy, lactation, pediatric use, renal impairment, and hepatic impairment are listed in the prescribing information structure, but the reporting safety language in the update remains focused on the adult indication and the hazards most likely to shape emergency use.
The revised labeling date is May 2022, while the drug label information page shows an updated date of November 9, 2026. Regardless of the administrative date stamp, the clinical message is unchanged: ATNAA is an emergency intramuscular antidote for adult organophosphorus nerve agent poisoning, and its value depends on speed, symptom recognition, and immediate escalation to definitive care. Its risks are the expected consequences of a powerful cholinergic antidote delivered under the unforgiving conditions of chemical exposure.